Business
Kalytera Announces Grant of Stock Options to Directors and Employees
Kalytera Announces Grant of Stock Options to Directors and Employees.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\nSAN FRANCISCO and TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" or \"Kalytera\") today announced that it has granted stock options on September 24, 2018 to certain directors and employees of the Company.  The stock options have an exercise price of $0.135 per common share and expire ten years from the date of grant.  One third of the options granted will vest on September 24, 2019 and the remaining options will vest in twenty-four (24) equal monthly installments commencing October 2019.\n Stock options to purchase 1,262,475 common shares of Kalytera were issued to each of Ron Erickson, Jeff Paley and Gary Leong, who are all independent members of the Company’s board of directors, and stock options to purchase 5,117,794 common shares of Kalytera were issued to Robert Farrell, a director and the Chief Executive Officer of the Company.  Stock options to purchase 250,000 common shares of Kalytera were issued to Victoria Rudman, the Company’s Interim Chief Financial Officer, while Drs. Prutchi-Sagiv and Yeshurun were granted stock options to purchase 400,000 common shares and 500,000 common shares of the Company, respectively. About Kalytera TherapeuticsKalytera Therapeutics, Inc. is pioneering the development of cannabidiol (CBD) therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (GVHD) and treatment of acute and chronic pain. Website Home: https://kalytera.co/News and Insights: https://kalytera.co/news/Investors: https://kalytera.co/investors/ Cautionary Statements Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements (\"forward-looking information\") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned cl...